8-K: Bicycle Therapeutics Announces Promising Clinical Results Across Oncology Pipeline at ESMO Congress 2024

Bicycle Therapeutics shared updated clinical results for three of its drug candidates, showing promising response rates and safety profiles in various cancer types.

Summary

• Bicycle Therapeutics presented updated clinical results for zelenectide pevedotin, BT5528, and BT7480 at the ESMO Congress 2024.
• Zelenectide pevedotin showed a 45% overall response rate (ORR) in metastatic urothelial cancer (mUC) with a median duration of response of 11.1 months.
• BT5528 demonstrated a 45% ORR in mUC patients in a specific dose expansion cohort and a 12% ORR in all advanced solid tumors.
• BT7480 showed a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors, with stable disease in 13 patients.
• The company also highlighted the low frequency and severity of treatment-related peripheral neuropathy with their Bicycle Toxin Conjugates (BTCs).
• Bicycle Therapeutics is continuing dose exploration for BT7480 in combination studies, starting with nivolumab.
• Additional data updates for zelenectide pevedotin in combination with pembrolizumab and as monotherapy in other cancers are planned for later this year.

Sentiment

Score: 8

Explanation: The document presents positive clinical results with promising response rates and improved safety profiles, suggesting a positive outlook for the company's drug candidates. The management's comments are also optimistic, further boosting the sentiment.

Positives

• Zelenectide pevedotin shows a promising 45% overall response rate in mUC, comparable to other drug conjugates but with improved tolerability.
• BT5528 demonstrates significant anti-tumor activity, particularly in mUC, with a 45% ORR in a specific cohort.
• Both zelenectide pevedotin and BT5528 have a relatively low incidence of peripheral neuropathy, a common side effect of similar therapies.
• BT7480 shows a favorable safety profile and preliminary antitumor activity, with ongoing dose exploration.
• The data suggests that the antibody-drug construct may be a primary driver of peripheral neuropathy rather than MMAE toxicity.

Negatives

• BT5528 showed a lower overall response rate of 12% across all advanced solid tumors.
• No objective responses were observed in patients with ovarian cancer treated with BT5528.
• Some patients experienced progressive disease while on zelenectide pevedotin.
• There were two unconfirmed partial responses with BT7480.

Risks

• The clinical trials are still ongoing, and the results may change.
• The company is still exploring the optimal doses for some of its drug candidates.
• The success of the drug candidates depends on the results of future clinical trials.
• There is a risk that the company may not achieve the intended benefits of its technology or partnerships.
• The company's actual results could differ from forward-looking statements due to various factors.

Future Outlook

Bicycle Therapeutics plans to share initial imaging data from its radiopharmaceutical pipeline and additional data for zelenectide pevedotin in bladder, breast, and lung cancer in the coming months. They also plan to assess BT5528 in combination with nivolumab, with results expected in 2025.

Management Comments

• Kevin Lee, Ph.D., CEO of Bicycle Therapeutics, stated that the data presented at ESMO continue to support the promising response and differentiated safety profiles of their Bicycle molecules.
• He also mentioned that zelenectide pevedotin continues to demonstrate an overall response rate in line with other drug conjugates for mUC, but with a marked improvement in tolerability.
• The CEO believes the data demonstrate the potential of their Bicycle technology platform to create differentiated medicines designed to help patients not only to live longer but also to live well.

Industry Context

This announcement is significant as it highlights the potential of Bicycle Therapeutics' novel bicyclic peptide technology in developing targeted cancer therapies. The results are being presented at a major oncology conference, ESMO, indicating the importance of these findings within the medical community. The focus on improved tolerability, particularly reduced peripheral neuropathy, addresses a key challenge in the field of drug conjugates.

Comparison to Industry Standards

• The 45% ORR for zelenectide pevedotin in mUC is comparable to other antibody-drug conjugates used in this setting, such as enfortumab vedotin, but with a potentially better safety profile.
• The 45% ORR for BT5528 in mUC in the expansion cohort is a strong result, especially considering the challenges in targeting EphA2.
• The low rates of peripheral neuropathy with Bicycle's BTCs are a notable improvement compared to other MMAE-based drug conjugates, which often have higher rates of this side effect.
• The stable disease observed with BT7480 is a positive sign, especially in difficult-to-treat cancers like NSCLC, and the ongoing dose exploration is in line with industry practices for novel immunotherapies.

Stakeholder Impact

• Shareholders may react positively to the promising clinical results and the potential for future growth.
• Patients with cancer may benefit from the development of new and more effective therapies.
• Employees may be motivated by the company's progress and the potential to make a difference in patients' lives.
• The company's success could lead to new partnerships and collaborations.

Next Steps

• The company will continue enrolling patients in the global Phase 2/3 Duravelo-2 registrational trial of zelenectide pevedotin.
• Additional data updates for zelenectide pevedotin in combination with pembrolizumab and as monotherapy in other cancers are planned for later this year.
• The company will assess BT5528 at 6.5 mg/m2 every two weeks in combination with nivolumab, with results expected in 2025.
• Dose exploration for BT7480 in combination studies, starting with nivolumab, will continue.

Key Dates

Keywords

Bicycle Therapeutics, Oncology, Zelenectide pevedotin, BT5528, BT7480, Metastatic Urothelial Cancer, Solid Tumors, Peripheral Neuropathy, ESMO Congress, Clinical Trials, Drug Conjugates